InsiderTrades

Form 4 for RGNX REGENXBIO Inc.

Accepted 2024-01-18 00:00:00 ET · period of report 2024-01-16 · accession 0001562180-24-000544 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2024-01-18 2024-01-16 RGNX Mills Kenneth T. Pres, CEO, Dir M - OptEx $3.76 +45.0K 453.0K +11% +$169.2K
DT 2024-01-18 2024-01-16 RGNX Mills Kenneth T. Pres, CEO, Dir S - Sale+OE $15.18 -45.0K 408.0K -10% -$683.1K
DT 2024-01-18 2024-01-16 RGNX Mills Kenneth T. Pres, CEO, Dir M - OptEx $0.00 -45.0K 141.4K -24% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-16 M A 45,000 $3.76 453,035 D — —
2 Common Common Stock 2024-01-16 S D 45,000 $15.18 408,035 D — — (F2) This transaction was executed in multiple trades at prices ranging from $14.52 to $15.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3 Derivative Stock Options (Right to Buy) 2024-01-16 M D 45,000 $0.00 141,354 D $3.76 · — to 2025-05-19 45,000 Common Stock (F3) The previously granted option, representing a right to purchase a total of 45,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 36 months thereafter.